1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By Tom Gallen

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

• Source: Shutterstock

Austrian biotech Marinomed has filed for insolvency as revenue expectations for the 2024 financial year could not be realized as anticipated.

The company reported in May that sales of its virus-blocking compound Carragelose had slumped to pre-pandemic levels as a three-year...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Haleon Lowers Sales Guidance On Challenging US Retail Environment

 
• By Tom Gallen

A challenging US retail environment, with consumers cautious around spending, hit Haleon's North America sales in the first half of 2025. With the picture unlikely to improve in the second half, Haleon has lowered its sales guidance for the full year.

PharmaSGP Increases Sales Forecast Ahead Of Delisting

 
• By Tom Gallen

German consumer health player expects 2025 sales to be €10m higher than previously forecast after a better than predicted showing in the year-to-date.

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

 
• By Tom Gallen

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.

People On The Move: Appointments at BioGaia, Assosalute, Bayer

 
• By Tom Gallen

A round-up of the latest European people moves: BioGaia hires new subsidiary head from L'Oréal; Assosalute gets new director; Bayer renews contract of CEO.

More from Ingredients & Safety

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By David Ridley

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”